Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model

Mohamed M. Sayed-Ahmed,* Amal Q. Darweesh and Amal J. Fatani

Department of Pharmacology; College of Pharmacy; King Saud University; Riyadh, Kingdom of Saudi Arabia

Key words: ifosfamide, Fanconi Syndrome, carnitine deficiency, cardiotoxicity, D-carnitine, mildronate, propionyl-L-carnitine

In addition to hemorrhagic cystitis, Fanconi Syndrome is a serious clinical side effect during ifosfamide (IFO) therapy. Fanconi syndrome is a generalized dysfunction of the proximal tubule which is characterized by excessive urinary excretion of glucose, phosphate, bicarbonate, amino acids and other solutes excreted by this segment of the nephron including L-carnitine. Carnitine is essential cofactor for β-oxidation of long-chain fatty acids in the myocardium. IFO therapy is associated with increased urinary carnitine excretion with subsequent secondary deficiency of the molecule. Cardiac abnormalities in IFO-treated cancer patients were reported as isolated clinical cases. This study examined whether carnitine deficiency and oxidative stress, secondary to Fanconi Syndrome, provoke IFO-induced cardiomyopathy as well as exploring if carnitine supplementation using Propionyl-L-carnitine (PLC) could offer protection against this toxicity. In the current study, an animal model of carnitine deficiency was developed in rats by D-carnitine-mildronate treatment Adult male Wistar albino rats were assigned to one of six treatment groups: the first three groups were injected intraperitoneally with normal saline, D-carnitine (DC, 250 mg/kg/day) combined with mildronate (MD, 200 mg/kg/day) and PLC (250 mg/kg/day), respectively, for 10 successive days. The 4th, 5th and 6th groups were injected with the same doses of normal saline, DC-MD and PLC, respectively for 5 successive days before and 5 days concomitant with IFO (50 mg/kg/day). IFO significantly increased serum creatinine, blood urea nitrogen (BUN), urinary carnitine excretion and clearance, creatine phosphokinase isoenzyme (CK-MB), lactate dehydrogenase (LDh), intramitochondrial acetyl-CoA/CoA-P and thiobarbituric acid reactive substances (TBARs) in cardiac tissues and significantly decreased adenosine triphosphate (ATp) and total carnitine and reduced glutathione (GSH) content in cardiac tissues. In cardiac-depleted rats, IFO induced dramatic increase in serum creatinine, BUN, CK-MB, LDH, cardiac clearance and intramitochondrial acetyl-CoA/CoA-P, as well as progressive reduction in total carnitine and ATP in cardiac tissues. Interestingly, PLC supplementation completely reversed the biochemical changes-induced by IFO to the control values. In conclusion, data from the present study suggest that: Carnitine deficiency and oxidative stress, secondary to Fanconi Syndrome, constitute risk factors and should be viewed as mechanisms during development of IFO-induced cardiotoxicity. Carnitine supplementation, using PLC, prevents the development of IFO-induced cardiotoxicity through antioxidant signalling and improving mitochondrial function.

Introduction

Ifosfamide (IFO) is an oxazaphosphorine alkylating agent which is commonly used in cancer chemotherapy and immunosuppressive protocols.1 Unfortunately, the optimal clinical usefulness of IFO is severely limited by a high incidence of nephrotoxicity in the form of Fanconi Syndrome especially in children.2,3 It is well documented that IFO is a prodrug that must be biotransformed by hepatic cytochrome P450 system to produce the active alkylating species, isophosphoramid mustard (IPM) and the urotoxic metabolite, acrolein, the main cause of hemorrhagic cystitis.1,3 IFO also undergoes N-dechloroethylation pathway to produce the toxic metabolites, 2 and 3-dechloroethylated compounds as well as chloroacetaldehyde (CAA), a substance that decomposed to give another potential toxic compound thiodiagonalic acid (TDGA). Earlier and recent studies reported that IFO therapy is associated with severe nephrotoxicity.4,5 It has been reported that local formation and accumulation of CAA in human kidney is the major cause of IFO-induced nephrotoxicity.6-8 In isolated rat kidney mitochondria, Nissim et al. reported that CAA inhibits NADH: ubiquinone oxidoreductase which disrupts oxidative phosphorylation, leading to multiple metabolic abnormalities, including elevation of NADH, decrease pyruvate dehydrogenase reaction and TCA cycle.7 Hence, despite the co-administration of mesna which has low reactivity with CAA, treatment with IFO is associated with severe proximal tubular dysfunction in the
form of Fanconi Syndrome, which is characterized by excessive urinary excretion of glucose, phosphate, bicarbonate, amino acids and other solutes handled by this segment of the nephron including L-carnitine.9,10

L-Carnitine is an endogenous compound that plays an important physiological role in the transfer of long-chain fatty acids across the inner membrane of mitochondria for their -oxidation and energy production.11 Kidney plays an important role in keeping the homeostasis of carnitine by conserving 95% of the filtered carnitine.12 The tubular reabsorption is compromised in IFO-treated patients suffering from nephrotoxicity thus, high renal loss of the compound persisted during the treatment.13 In addition, it is well documented that cachectic cancer patients are especially at risk for carnitine deficiency due to decreased intestinal absorption and increased renal losses.14-16 It has been reported that IFO therapy is associated with increased secretion of carnitine derivatives in the urine with subsequent secondary deficiency of the molecule.13 It is well documented that CAA and TDGA, the two major toxic metabolites of IFO, inhibit the oxidation of long-chain fatty acids (carnitine-dependent) but not medium chain-fatty acids (carnitine-independent) indicating that these compounds either sequester carnitine or inhibit long-chain fatty acid oxidation by inhibition of carnitine palmitoyl transferase-I (CPT I).6,19 Although kidney is the main organ responsible for endogenous synthesis of L-carnitine, up to date in the literature, we could not find any study investigating the effects of IFO on renal handling of carnitine and its metabolic consequences on the myocardium under condition of carnitine depletion and supplementation. Therefore, this study has been initiated to investigate the effects of the standard IFO-induced Fanconi Syndrome regimen on serum, urine and cardiac carnitine levels in normal and carnitine depleted rats and its relationship to IFO-induced cardiotoxicity. The second aim was to gain insights into the possibility of mechanism-based protection of the heart by PLC against side effects of IFO.

Results

Table 1 shows the effects of IFO on serum creatinine and BUN in PLC-supplemented and carnitine-depleted rats. IFO resulted in a highly significant 233 and 155%, increase in serum creatinine and BUN, respectively as compared to control. Treatment with DC-MD for 5 days before and 5 days concomitant with IFO resulted in a significant 53 and 102% increase in the levels of serum creatinine and BUN, respectively as compared to IFO alone. Interestingly, administration of PLC 5 days before and 5 days concomitant with IFO resulted in complete reversal of the increases in serum creatinine and BUN to the control values.

The effects of IFO on urinary carnitine excretion and carnitine clearance in PLC-supplemented and carnitine-depleted rats are shown in Table 2. Administration of IFO (50 mg/kg/day) for 5 days resulted in 2- and 2.3-folds increase in carnitine excretion and clearance, respectively, as compared to the control group. Treatment of carnitine-depleted rats with IFO resulted in a significant increase in both excretion and clearance of carnitine, as compared to IFO alone. Carnitine supplementation by daily administration of PLC for 5 days before and 5 days concomitant with IFO resulted in 1.8- and 0.8-folds increase in carnitine excretion and clearance, respectively, as compared to the

<table>
<thead>
<tr>
<th>Treatment groups</th>
<th>Serum creatinine (mg/dl)</th>
<th>BUN (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.57 ± 0.04</td>
<td>52 ± 1.43</td>
</tr>
<tr>
<td>DC-MD</td>
<td>0.57 ± 0.04</td>
<td>60 ± 2.34</td>
</tr>
<tr>
<td>PLC</td>
<td>0.54 ± 0.04</td>
<td>46 ± 3.18</td>
</tr>
<tr>
<td>IFO</td>
<td>1.9 ± 0.22</td>
<td>133 ± 8.92</td>
</tr>
<tr>
<td>IFO plus DC-MD</td>
<td>2.9 ± 0.24</td>
<td>277 ± 16.5</td>
</tr>
<tr>
<td>IFO plus PLC</td>
<td>0.94 ± 0.15</td>
<td>57 ± 1.43</td>
</tr>
</tbody>
</table>

Rats were randomly divided into six different groups of 10 animals each: Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), PLC (carnitine supplemented group), IFO, DC-MD plus IFO and PLC plus IFO. Carnitine depletion was induced in rats by daily intraperitoneal injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) for 10 successive days. Fanconi Syndrome was induced in rats by administration of IFO (50 mg/kg/day, I.p.) for 5 successive days. IFO-carnitine depleted rats were given the same doses of DC-MD for 5 days before and 5 days concomitant with IFO. IFO-carnitine supplemented rats were given the same doses of PLC for 5 days before and 5 days concomitant with IFO. At the end of the treatment protocol, serum creatinine and BUN, indices of nephrotoxicity, were measured in serum. Data are presented as mean ± S.E.M. (n = 10). *, # and $ indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.

<table>
<thead>
<tr>
<th>Treatment groups</th>
<th>Urinary carnitine excretion (µmol/day)</th>
<th>Carnitine clearance (ml/min) x 10^2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.53 ± 0.06</td>
<td>0.85 ± 0.14</td>
</tr>
<tr>
<td>DC-MD</td>
<td>2.78 ± 0.50</td>
<td>9.75 ± 2.66</td>
</tr>
<tr>
<td>PLC</td>
<td>10.06 ± 0.88</td>
<td>6.97 ± 0.66</td>
</tr>
<tr>
<td>IFO</td>
<td>1.61 ± 0.11</td>
<td>3.50 ± 0.78</td>
</tr>
<tr>
<td>IFO plus DC-MD</td>
<td>4.17 ± 0.68</td>
<td>9.39 ± 1.42</td>
</tr>
<tr>
<td>IFO plus PLC</td>
<td>4.53 ± 1.79</td>
<td>4.52 ± 2.14</td>
</tr>
</tbody>
</table>
control values. Administration of DC-MD for 10 successive days resulted in a significant 4- and 10.5-folds increase as compared to the control group.

Table 3 shows the effects of IFO on the activity of serum CK-MB and LDH, in PLC-supplemented and carnitine-depleted rats. Administration of IFO resulted in a significant 49 and 79% increase in serum CK-MB and LDH, respectively, as compared to the control group. Treatment with either PLC (carnitine-supplemented rats) or combined DC-MD (carnitine-depleted rats) for 10 successive days showed non-significant changes. Treatment with DC-MD for 5 days before and 5 days concomitant with IFO resulted in a significant 54% increase in the activity of CK-MB and 12% elevation in LDH as compared to IFO alone. Interestingly, administration of PLC for 5 days before and 5 days after IFO resulted in a complete reversal of IFO-induced increase in serum CK-MB and LDH to the control values.

Figure 1 shows the effects of IFO on the levels of total carnitine in serum (Fig. 1A), total carnitine in cardiac tissues (Fig. 1C) and ATP concentration in cardiac tissues (Fig. 1B) from PLC-supplemented and carnitine-depleted rats. Administration of PLC for 10 successive days resulted in a significant 126% increase in serum total carnitine, whereas, administration of DC-MD for 10 successive days resulted in a non-significant change as compared to the control group. Treatment with IFO resulted in non-significant changes in serum carnitine level as compared to the results of the control group. Treatment with DC-MD for 5 days before and 5 days concomitant with IFO decreased serum carnitine levels as compared to the results of the control, IFO and DC-MD groups. Interestingly, daily administration of PLC for 5 days before and 5 days concomitant with IFO resulted in a significant 87 and 91% increase in serum carnitine as compared to the results of the control and IFO groups, respectively.

On the other hand, IFO alone resulted in a significant 45% decrease in total carnitine level in cardiac tissues, while administration of DC-MD alone caused a significant 42% decrease as compared to the control group. Combined treatment with IFO and DC-MD resulted in a significant 90, 82 and 80% decrease in the total carnitine level in cardiac tissues as compared to the control, DC-MD and IFO groups, respectively. Moreover, challenging with IFO alone significantly decreased ATP levels by 52% in cardiac tissues as compared to control. Carnitine-depleted rats showed significant 45% reduction in cardiac ATP levels, while combining modality also lowered the ATP content by about 86, 74 and 72% compared to either control, DC-MD and IFO given alone, respectively. Interestingly, carnitine supplementation by daily administration of PLC to animals receiving IFO resulted in a complete reversal of IFO-induced decrease in total carnitine and ATP levels in cardiac tissues to the control values.

Figure 2 shows the effects of IFO on the level of CoA-SH (Fig. 2A), acetyl-CoA (Fig. 2B) and acetyl-CoA/CoA-SH (Fig. 2C) in heart mitochondria isolated from carnitine-depleted and supplemented rats. Treatment with previously mentioned regimen of IFO and DC-MD resulted in a significant 46 and 26% decrease in CoA-SH level and a significant 79 and 57% increase in acetyl-CoA/CoA-SH ratio as compared to the control and IFO groups, respectively. Administration of IFO to carnitine-depleted rats resulted in a significant 64 and 33% decrease in CoA-SH level in isolated rat heart mitochondria, thus raising the ratio to 52 and 41% as compared to the results of the control and IFO groups, respectively. Interestingly, daily administration of PLC to IFO-treated rats resulted in a complete reversal of IFO-induced changes in CoA-SH and acetyl-CoA/CoA-SH level in mitochondria to the control values.

Table 4 shows the effects of IFO on oxidative stress biomarkers, TBARS and GSH in cardiac tissues. IFO produced GSH nadir amounted to 60% and dramatically elevated the TBARS levels in cardiac tissues by 80% compared to control group. Repeated administration of DC-MD followed by IFO resulted in a significant 29 and 223% increase in the level of GSH in cardiac tissues as compared to the control and IFO groups, respectively. On the other hand, the treatment modality resulted in a significant 44% decrease in the level of TBARS in cardiac tissues as compared to IFO group. Pre-treatment with PLC followed by IFO challenge thereafter resulted in a complete reversal of IFO-induced increase in TBARS and decrease in GSH level in cardiac tissues to the control values.

**Discussion**

Recent studies in our laboratory20-24 and others25,26 have demonstrated the progression of cisplatin, carboplatin, cyclophosphamide and gentamicin-induced nephrotoxicity, cardiomyopathy...
and hepatotoxicity under condition of carnitine deficiency and that carnitine supplementation attenuates these multiple organ toxicity. Although it is well documented that IFO therapy is associated with Fanconi Syndrome, we could not find any study investigating the effects of IFO on renal handling of carnitine and its metabolic consequences under condition of carnitine depletion and supplementation. Taken together, this prompted us to investigate, for the first time, whether carnitine deficiency secondary to IFO-induced Fanconi Syndrome plays a role and should be viewed as a risk factor during development of IFO-induced cardiomyopathy as well as exploring if carnitine supplementation using PLC could offer protection against this toxicity.

Results from this study demonstrated that IFO increased nephrotoxicity indices, serum creatinine (233%) and BUN (155%) which precipitates IFO-induced Fanconi Syndrome. Under similar experimental condition, several studies reported that administration of IFO (50 mg/kg) for 5 successive days is associated with severe nephrotoxicity in the form of Fanconi Syndrome. In carnitine depleted rats, IFO caused progressive increase in BUN and serum creatinine which was parallel to the marked increase in urinary carnitine excretion and clearance (Tables 1 and 2). This effect could be due to carnitine deficiency with subsequent impairment of fatty acid oxidation and shifting metabolism into carnitine-independent or non-lipid energy substrates. This speculation is consistent with data presented by Ahmed, et al. which reported that carnitine supplementation to patients undergoing hemodialysis decreased protein catabolism, thereby, reducing serum concentration of the products of protein catabolism, including BUN and creatinine.

Cardiotoxicity occurs during therapy with several cytotoxic drugs and may be the dose limiting factor in cancer treatment. It can be responsible for long term side effects causing severe morbidity in surviving cancer patients. Although IFO has not been added to the list of antineoplastic therapies associated with major cardiac complications, its cardiotoxicity was reported as isolated clinical cases in cancer patients receiving IFO in combination with other anticancer drugs. It has been reported that high doses of the alkylating drugs cyclophosphamide and IFO may result in a reversible heart failure and life-threatening arrhythmias. Cardiac effects reported with IFO therapy include supraventricular arrhythmias, ventricular premature contraction, dilated cardiomyopathy and severe refractory congestive heart failure. In this context, the current study addressed the possible contribution of carnitine deficiency as a risk factor in IFO-induce cardiotoxicity.

Data presented here demonstrated that IFO increased serum LDH and CK-MB. This increase in cardiac enzymes could be due to IFO-induced generation of reactive oxygen species (ROS) and lipid peroxidation of cardiac membranes with the consequent leakage of these enzymes from damaged myocytes. The contribution of oxidative and nitrosative stress in IFO and cyclophosphamide-induced multiple organ toxicity has been recently reported. It is well documented that ROS and oxidative stress play an important role in organ dysfunction induced by anticancer drugs. Increased oxidative stress biomarkers and

Figure 1. Effect of ifosfamide (IFO) on the levels of total carnitine in serum (A), total carnitine in cardiac tissues (B) and ATP concentration in cardiac tissues (C) from propionyl-l-carnitine (PLC)-supplemented and carnitine-depleted rats. Rats were randomly divided into 6 different groups of 10 animals each: Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), PLC (carnitine supplemented group), IFO, DC-MD plus IFO and PLC plus IFO. Carnitine depletion was induced in rats by daily intraperitoneal injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) for 10 successive days. Carnitine supplementation was induced in rats by daily intraperitoneal injection of PLC (250 mg/kg/day) for 10 successive days. Fanconi Syndrome was induced in rats by administration of IFO (50 mg/kg/day, I.P) for 5 successive days. IFO-carnitine depleted rats were given the same doses of DC-MD for 5 days before and 5 days concomitant with IFO. IFO-carnitine supplemented rats were given the same doses of PLC for 5 days before and 5 days concomitant with IFO. At the end of the treatment protocol, total carnitine was measured in serum whereas ATP and total carnitine were measured in cardiac tissues. Data are presented as mean ± S.E.M. (n = 10). *, # and $ indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.
depletion of enzymatic and non-enzymatic antioxidants have been reported in cardiopulmonary and other metabolic disorders. Fascinatingly, administration of PLC for 5 days before and 5 days concomitant with IFO completely prevented the increase in LDH and CK-MB induced by IFO, suggesting that PLC may have potential protective effect against IFO-induced cardiac damage. This effect could be due to cardiac membrane stabilization by the L-carnitine portion of PLC which interacts with sarcotubular phospholipids and mitochondrial membranes with subsequent decrease in the release of cardiac enzymes. Moreover, PLC through its reported antioxidant defence in the heart and other tissues could protect myocytes against IFO-induced lipid peroxidation. The antioxidant effect of PLC has been confirmed by our results which have reported that PLC induced complete reversal of IFO-induced increase in TBARS and decrease in GSH in cardiac tissues to the control values. More recently, the antioxidant and anti-inflammatory effects of L-carnitine and PLC have been reported. In contrast, administration of IFO to carnitine-depleted rats produced a progressive increase in the activities of LDH and CK-MB. It is reported that IFO treatment is associated with nephrotoxicity in the form of Fanconi Syndrome. The IFO regimen used in current study (50 mg/kg/day) for 5 successive days proves to be nephrotoxic as evidenced by the increase in serum creatinine and BUN in rats. Quezado, et al. reported that development of congestive heart failure in patients with lymphoma was significantly correlated with the doubling in serum creatinine after IFO treatment. Our results are unique since no available experimental or clinical data about the role of endogenous carnitine system during development of IFO-induced multiple organ toxicity.

In the current study, the observed decrease in cardiac carnitine content could be a secondary event following IFO-induced inhibition of endogenous synthesis and/or inhibition of tubular reabsorption of carnitine. Since kidney is the major site for endogenous carnitine biosynthesis and 95% of filtered carnitine is reabsorbed by the proximal tubules of the nephron, therefore, IFO-induced Fanconi Syndrome may lead to inhibition of endogenous carnitine biosynthesis and increases its urinary losses with the consequent secondary deficiency of the molecule. This is in line with current data which showed that urinary carnitine excretion and carnitine clearance were increased by administration of IFO. The present results are in line with the only clinical study performed on five patients and reported that IFO increased urinary carnitine excretion. These results are in good agreement with earlier and recent studies which have reported that increased urinary excretion of carnitine is an early marker in chemotherapy-induced nephrotoxicity. Moreover, the role of IFO metabolites in kidney and heart damage cannot be ruled out. Inhibition of the oxidation of long-chain fatty acids by CAA and TDGA has been previously reported.

Data reported here demonstrate that IFO administration significantly decreased intramitochondrial free CoA-SH, an indispensable activator in Kreb’s cycle and β-oxidation. This effect could be explained on the basis of the high reactivity of IFO metabolites including CAA, TDGA, IPM and acrolin, with SH-containing molecules. Earlier studies have documented that the
Table 4. Effect of ifosfamide (IFO), propionyl-l-carnitine (PLC), D-carnitine-mildronate (DC-MD) and their combination on the levels of thiobarbituric acid reactive substances (TBARS) and reduced glutathione (GSH) in rat cardiac tissues.

<table>
<thead>
<tr>
<th>Treatment groups</th>
<th>TBARS (nmol/g wet tissue)</th>
<th>GSH (nmol/g wet tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>249.60 ± 14.9</td>
<td>0.70 ± 0.02</td>
</tr>
<tr>
<td>DC-MD</td>
<td>118.01 ± 14.7*</td>
<td>1.02 ± 0.09</td>
</tr>
<tr>
<td>PLC</td>
<td>113.21 ± 9.7*</td>
<td>1.23 ± 0.14*</td>
</tr>
<tr>
<td>IFO</td>
<td>449.14 ± 33.9*</td>
<td>0.280 ± 0.03*</td>
</tr>
<tr>
<td>IFO plus DC-MD</td>
<td>249.10 ± 33.8*</td>
<td>0.90 ± 0.08</td>
</tr>
<tr>
<td>IFO plus PLC</td>
<td>243.60 ± 24.8*</td>
<td>0.89 ± 0.09</td>
</tr>
</tbody>
</table>

Rats were randomly divided into 6 different groups of 10 animals each: Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), PLC (carnitine supplemented group), IFO, DC-MD plus IFO and PLC plus IFO. Carnitine depletion was induced in rats by daily intraperitoneal injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) for 10 successive days. Carnitine supplementation was induced in rats by daily intraperitoneal injection of PLC (250 mg/kg/day) for 10 successive days. Fanconi Syndrome was induced in rats by administration of IFO (50 mg/kg/day, I.P.) for 5 successive days. IFO-carnitine depleted rats were given the same doses of DC-MD for 5 days before and 5 days concomitant with IFO. IFO-carnitine supplemented rats were given the same doses of PLC for 5 days before and 5 days concomitant with IFO. At the end of the treatment protocol, TBARS and GSH, oxidative stress biomarkers, were measured in rat cardiac tissues. Data are presented as mean ± S.E.M. (n = 10), * and # indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test. Data are presented as mean ± S.E.M. (n = 10), *, # and $ indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.

In the current study, utilizing PLC as a source of carnitine prevented IFO and DC-MD induced decrease in cardiac carnitine content, intramitochondrial CoA-SH and ATP production by replenishing the myocardium with adequate carnitine for energy production. A possible explanation for this is that, in the mitochondria, PLC has higher affinity for CoA-SH:carnitine acetyltransferase (CAT) and being metabolized into free L-carnitine and propionyl-CoA. The L-carnitine portion of PLC will increase fatty acid oxidation by increasing its mitochondrial transport through CPT-I and/or decreasing the intramitochondrial acetyl-CoA/CoA-SH ratio. The propionyl-CoA formed in mitochondria from PLC metabolism will stimulate substrates oxidation since it can be converted into succinyl-CoA in a reaction mediated by propionyl-CoA carboxylase, thus increasing the flux of acetyl-CoA through TCA cycle. In summary, this study suggests that IFO is usually associated in the setting of nephrotoxicity and increased urinary carnitine loss, with severe cardiotoxicity.

**Materials**

Holoxan vials (Baxter oncology GmbH, Germany) were gifted from King Khalid University Hospital drug store, King Saud University, Kingdom of Saudi Arabia. Each holoxan vial contains 1 g IFO in a dry lyophilized powder form. The content of each vial was freshly dissolved in sterile water for injection immediately before injection. Propionyl-L-carnitine (PLC), D-carnitine (DC) and Mildronate (MD) were kindly supplied by Dr. Zaven Orfalian, Sigma-Tau Pharmaceuticals, Pomezia, Italy. It has been supplied as white powder in a non-commercial plastic bottles contains 100 g and it was freshly dissolved in normal saline prior to injection. All other chemicals used were of the highest analytical grade.

**Animals.** Adult male Wistar albino rats, weighing 180–200 g, were obtained from the Animal Care Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia and were housed in metabolic cages under controlled environmental conditions (25°C and a 12 h light/dark cycle). Animals had free access to pulverized standard rat pellet food and tap water. The protocol of this study has been approved by Research Ethics Committee of College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

**Experimental design.** Experimental animal model of carnitine deficiency was developed according to Paulson and Shug, Whitmer, and Tsoko et al. In the current study, carnitine depletion was induced in rats by daily intraperitoneal (I.P.) injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) for 10 successive days according to previously published studies. Depletion of L-carnitine by DC occurs via an exchange of the D-and L-isomers across the cell membrane. Moreover, DC possesses an inhibitory effect upon carnitine transferase enzymes and competitive inhibitory effect upon L-carnitine uptake. Depletion of L-carnitine by MD occurs via inhibition of gamma-butyrobetaine hydroxylase, a key enzyme in the biosynthesis of carnitine. Also, Fanconi Syndrome was induced in rats by administration of IFO (50 mg/kg/day, I.P.) for 5 successive days.
Determination of total carnitine in serum, urine and cardiac tissues. Total carnitine concentrations were determined in serum, urine and cardiac tissues according to the method reported by Prieto et al.\textsuperscript{59} In brief, carnitine reacts with acetyl-CoA forming acetyl carnitine in a reaction mediated by carnitine acetyltransferase enzyme. The liberated CoA-SH reacts with 5,5-dithiobis-(2-nitrobenzoic acid) and forming thiophenolate ion, whose generation is proportional to the amount of carnitine and can be measured spectrophotometrically at 412 nm. Serum, urine and heart tissues were deproteinized with equal volume of ice-cold 0.6 M perchloric acid and allowed to stand in an ice bath for 10 min. The mixture was centrifuged at 1,000 g at 4°C for 5 min. The supernatant was used directly for measuring free carnitine after neutralization with 1.2 M potassium carbonate. For the assay of total carnitine, a part of supernatant was mixed with 1 M KOH and incubated at 37°C for 20 min for the hydrolysis of acylcarnitines. Carnitine level was computed from a calibration curve for carnitine hydrochloride.

**Methods**

Assessment of serum creatinine and blood urea nitrogen (BUN). Serum creatinine and BUN concentrations were measured spectrophotometrically according to the methods of Fabiny and Ertingshausen\textsuperscript{55} and Tabacco et al.\textsuperscript{56} respectively.

Assessment of serum creatine kinase (CK-MB) and lactate dehydrogenase (LDH) activity. Serum activities of LDH and CK-MB were determined according to the methods of Buhl and Jackson\textsuperscript{57} and Wu and Bowers,\textsuperscript{58} respectively.

Determination of total carnitine in serum, urine and cardiac tissues. Total carnitine concentrations were determined in serum, urine and cardiac tissues according to the method of Henderson and Jessup\textsuperscript{53} and Garrow and Jackson\textsuperscript{54} respectively.

Assessment of serum creatine kinase iso-enzyme (CK-MB) and total carnitine. Hearts were quickly excised, washed with saline, blotted with a piece of filter paper and homogenized, in normal saline or 6% perchloric acid as indicated in the procedures of measurement of each parameter, using a Branson sonifier (250, VWR Scientific, Danbury, CT).

According to the previously published protocols,\textsuperscript{7,10,54} To achieve the ultimate goals of this study, a total of 60 adult male Wistar albino rats were used and divided at random into 6 groups of 10 animals each. Rats of Group 1 (control group) were received I.P. injection of normal saline (2.5 ml/kg/day) for 10 successive days. Animals in Group 2 (carnitine-depleted group) were given DC (250 mg/kg/day, I.P.) and MD (200 mg/kg/day, I.P.) for 10 successive days. Animals in Group 3 (carnitine-supplemented group) were given PLC (250 mg/kg/day, I.P.) for 10 successive days. Rats of Group 4 (IFO group) were received normal saline for 5 successive days followed by IFO (50 mg/kg/day, I.P.) for 5 successive days. Rats of Group 5 (IFO-carnitine depleted rats) were given the same doses of DC-MD as group 2 for 5 days before and 5 days concomitant with IFO as group 4. Rats of Group 6 (IFO-carnitine supplemented rats) were given the same doses of PLC as Group 3 for 5 days before and 5 days concomitant with IFO as Group 4. The following experimental table outlines the sequence of studies for each experimental animal model used.

<table>
<thead>
<tr>
<th>Group number</th>
<th>Types and duration of treatments (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal saline</td>
</tr>
<tr>
<td>2</td>
<td>D-carnitine combined with mildronate</td>
</tr>
<tr>
<td>3</td>
<td>Normal saline</td>
</tr>
<tr>
<td>4</td>
<td>Normal saline</td>
</tr>
<tr>
<td>5</td>
<td>D-carnitine combined with mildronate</td>
</tr>
<tr>
<td>6</td>
<td>Propionyl-L-carnitine</td>
</tr>
</tbody>
</table>

Methods

Assessment of serum creatinine and blood urea nitrogen (BUN). Serum creatinine and BUN concentrations were measured spectrophotometrically according to the methods of Fabiny and Ertingshausen\textsuperscript{55} and Tabacco et al.\textsuperscript{56} respectively.

Assessment of serum creatine kinase (CK-MB) and lactate dehydrogenase (LDH) activity. Serum activities of LDH and CK-MB were determined according to the methods of Buhl and Jackson\textsuperscript{57} and Wu and Bowers,\textsuperscript{58} respectively.

Determination of total carnitine in serum, urine and cardiac tissues. Total carnitine concentrations were determined in serum, urine and cardiac tissues according to the method of Henderson and Jessup\textsuperscript{53} and Garrow and Jackson\textsuperscript{54} respectively.
Determination of adenosine triphosphate in cardiac tissues. Adenosine triphosphate was determined in heart tissues using HPLC system (Jasco Corporation, Ishikawa-Cho, Hachioji, Tokyo, Japan) according to Botker, et al. In brief, heart tissue was homogenized in ice-cold 6% perchloric acid, centrifuged at 1,000 rpm for 15 min at 0.5°C and the supernatant fluid was injected into HPLC after neutralization to pH 6–7. Chromatographic separation was performed at a flow rate of 1.2 ml/min, using ODS-Hypersil, 150 x 4.6 mm I.D., 5 μm column (Supelco SA, Gland, Switzerland) and 75 mM ammonium dihydrogen phosphate as mobile phase. The ATP peaks were eluted at 3.2 min and the UV detector was operated at 254 nm.

Determination of reduced glutathione and lipid peroxidation in cardiac tissues. The tissue levels of the acid soluble thiols, mainly GSH, were assayed spectrophotometrically at 412 nm, according to the method of Ellman. Using a Shimadzu (Tokyo, Japan) spectrophotometer. The contents of GSH were expressed as mmol/g wet tissue. The degree of lipid peroxidation in cardiac tissues was determined by measuring thiobarbituric acid reactive substances (TBARS) in the supernatant tissue from homogenate. The homogenates were centrifuged at 3,500 rpm and supernatant was collected and used for the estimation of TBARS. The absorbance was measured spectrophotometrically at 532 nm and the concentrations were expressed as nmol TBARS/g wet tissue.

Statistical analysis. Differences between obtained values (mean ± SEM, n = 10) were carried out by one way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison test. p ≤ 0.05 was taken as a criterion for a statistically significant difference.

Conclusions

Data from this study suggest that: (1) serum and urine carnitine levels should be viewed as markers that indicate early toxicity and should be monitored during IFO-therapy. (2) oxidative stress and carnitine deficiency provoke IFO-induced cardiotoxicity. (3) carnitine supplementation, using PLC prevents the development of IFO-induced cardiotoxicity through improving mitochondrial function and antioxidant signalling. It would be worthwhile considering the addition of PLC as adjunctive therapy to reduce cancer chemotherapy related complications.

Acknowledgements

The present work was supported by operating grant from King Abdulaziz City for Science and Technology (AT-16-94).

References


